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Thrombocytopenia (TCP) (platelet count <150 × 
109/L) during pregnancy often causes anxiety among 
both patients and healthcare practitioners. It occurs 
in 5 - 8% of pregnancies, the prevalence depending 
on whether it is associated with medical disorders or 
not.[1,2] Gestational TCP (gTCP), also known as incidental or benign 
TCP of pregnancy, accounts for approximately 80% of all cases of 
TCP occurring in pregnancy[1] and typically develops in the late 
second or third trimester when physiological haemodilution leads 
to an increased mean platelet volume and subsequent accelerated 
consumption. Women with gTCP are usually asymptomatic, their low 
platelet count being detected as part of routine antenatal screening. 
Fetal TCP is usually mild and transient, requiring no intervention. [3] 
A history of gTCP is sometimes obtained, as there is the potential 
for it to recur. A recurrence rate of 13.6% was noted in a series 
of 22  cases,[4] while among 37 patients with gTCP, Ruggeri et al.[3] 
reported 100% recurrence in 4 women who had repeat pregnancies.[3]
gTCP is usually mild (platelet count 100 - 150 × 109/L), and 
al though the minimum threshold has never been established, counts 
of ≤70 × 109/L are uncommon.[5] Severe TCP (≤50 × 109/L) is rare, 
occurring in ≤0.1% of pregnancies.[6] In these cases, pathological 
causes of increased destruction or utilisation of platelets such as pre-
eclampsia/eclampsia, the HELLP syndrome (haemolysis, elevated 
liver enzymes and low platelet count), and microangiopathies 
such as thrombotic thrombocytopenic purpura, (auto)immune 
thrombocytopenic purpura, haemolytic uraemic syndrome and 
haemolysis are likely. Viral infections such as viral hepatitis and 
infection with cytomegalovirus and HIV may also cause TCP.
In the era of HIV, particularly in South Africa (SA), where the 
seroprevalence in the antenatal population exceeds 25%, clinicians 
may not be able to differentiate gTCP from that associated with HIV. 
TCP has been reported to be present in 5 - 9% of patients who have 
HIV infection but are asymptomatic, and in 21 - 40% of those with 
AIDS.[6,7] Although TCP was initially thought to occur early in the 
course of HIV infection, reports have shown a correlation between 
TCP and low CD4 counts.[6,7] Moreover, TCP has been shown to 
correlate with a poorer prognosis and rapid progression to AIDS. [7,8] 
Transient TCP is a feature of the acute retroviral syndrome seen in 
primary HIV infection.[9] The two mechanisms involved in HIV-
associated TCP are thought to be immune-mediated destruction 
of platelets (in early infection) and a defect in platelet production 
(in advanced disease).[8] HIV also directly infects megakaryocytes, 
causing apoptosis and dysmegakaryopoiesis.[8] Individuals with HIV-
associated TCP have a clinical presentation and response to therapy 
similar to that of idiopathic (immune) thrombocytopenic purpura 
(ITP).[10] Apart from the severity and the time of onset of TCP in 
pregnant women with ITP (being more severe and occurring in 
earlier gestation), there is as yet no diagnostic test to differentiate 
gTCP from ITP, as circulating antibodies may be found in both 
conditions.[11]
There are limited data on the prevalence of gTCP in HIV-infected 
women. In a clinical setting where patients may arrive unbooked and 
in labour, or without a previous platelet count, it becomes important 
to establish the role of HIV in TCP.
Methods
This was a sub-analysis of data from a prospective longitudinal 
study aimed at determining the effect of HIV on postpartum 
infectious morbidity. The cohort comprised HIV-infected (n=675) 
and HIV-uninfected (n=648) women attending King Edward VIII 
Hospital, Durban, SA, between 2005 and 2007. Participants were 
recruited at ≥36 weeks’ gestation. They had to be at low risk with 
no obstetric morbidities, and eligible for a vaginal delivery. Ethical 
approval for the parent study was obtained from the University of 
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infected (6.0%) and HIV-uninfected women (4.7%) (p=0.292). Among the HIV-infected women, who were not receiving antiretroviral 
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KwaZulu- Natal BioMedical Research Ethics 
Committee (Ref. H031/01).
At baseline all women had full blood 
counts (FBCs), and CD4 counts if HIV-
infected. They were reviewed on three 
occasions in the post-delivery period, and 
tests were repeated 6 weeks after delivery. 
TCP was defined as a platelet count of 
≤150 × 109/L. It was regarded as severe if the 
platelet count was ≤50 × 109/L.
Results
Results were available for 1 311 women 
(669 HIV-infected and 642 HIV-uninfected) 
at baseline, and for 897 (461 (68.9%) of 
the HIV-infected and 436 (67.9%) of the 
HIV-uninfected) women at 6 weeks. None 
of the HIV-infected participants received 
combination antiretroviral therapy (ART), 
as the standard of care at the time was 
only single-dose nevirapine. The HIV-
infected and HIV-uninfected groups were 
comparable in terms of age, parity and body 
mass index (Table 1). The baseline FBC 
results are also shown in Table 1. HIV-
infected women had significantly lower 
baseline haemoglobin (Hb) concentrations 
and total white cell counts (WCCs) than 
HIV-uninfected women. The mean Hb at 
baseline was 11.1 g/dL for HIV-infected 
women and 11.7 g/dL for HIV-uninfected 
women (p<0.001). Twenty-three percent of 
the women had an Hb of ≤10.5 g/dL; these 
comprised 30.1% of the HIV-infected group 
compared with 16.4% of the HIV-uninfected 
group (p<0.001). The mean CD4 count of 
the HIV-infected women was 453 cells/µL at 
enrolment, increasing by 22% to a mean of 
552 cells/µL at 6 weeks postpartum. Women 
with CD4 counts of <200 cells/µL (11.1% of 
the HIV-infected population) had a mean 
CD4 count at enrolment of 129 cells/µL and 
a mean count of 131 cells/µL 6 weeks after 
delivery.
The mean platelet count was 243.2 × 109/L 
in the HIV-infected group (range 84 - 533) 
and 247.4 × 109/L in the HIV-uninfected 
group (range 26 - 597) (p=0.354) (Table 1). 
The incidence of gTCP was 40/669 (5.9%) 
in the HIV-infected and 30/642 (4.7%) in 
the HIV-uninfected women at baseline 
(relative risk (RR) 1.28; 95% confidence 
interval (CI) 0.81 - 2.03; p=0.292) (Table 
2). The TCP was mild in both groups, with 
only 3 HIV-uninfected and 4 HIV-infected 
women in each group having platelet counts 
of ≤100 × 109/L.
Among the HIV-infected women, TCP 
occurred at all ranges of CD4 counts and 
was not associated with immunosuppression 
(CD4 count <200 cells/µL). On the contrary, 
TCP occurred with increasing frequency 
with increasing CD4 counts (Table 2). The 
non-parametric test showed a low corre-
lation of 0.062. Three participants (all HIV-
infected) were found to have puerperal sepsis 
(endometritis), their infection resolving on 
first-line antibiotics.
For 461 HIV-infected women and 436 
HIV-uninfected women, both the base-
line and 6 weeks post-delivery platelet 
measurements were available. Eleven women 
had TCP at the 6-week assessment (6 HIV-
infected women (1.3%) and 5 HIV-uninfected 
women (1.2%)) (p=0.881) (Table  3). TCP 
had persisted from the antenatal period 
in 3 women in each HIV group (total 6); 
the remainder (3  HIV-infected and 2 HIV-
uninfected women) were new cases of TCP. 
The correlation between platelet counts and 
CD4 counts at baseline and 6 weeks for the 
11 women with TCP in the postpartum 
period is shown in Table 4. Of the 3 HIV-
infected women with persistent TCP after 
the first assessment, only 1 (patient 3) was 
immunosuppressed according to the CD4 
count. Of the 3 who had developed TCP for 
the first time in the postnatal period, only 1 
(patient 4) was immunosuppressed.
Discussion
gTCP develops in up to 5% of all preg-
nancies in the third trimester.[1] In the 
present study the overall prevalence of 
TCP during pregnancy was 5.3%, and there 
was no statistical difference in the preva-
lence between women with and without 
HIV infection. Mandelbrot et al.[11] found a 
comparable prevalence of TCP among HIV-
infected pregnant women of 3.2%; however, 
these authors associated >80% of cases of 
TCP with HIV-positive status despite the 
study having no HIV-uninfected controls. 
In the present study, the prevalence of 
severe TCP (<50 × 109/L) was very low 
despite half of the patients being HIV-
infected. In a study of patients of unknown 
HIV status, with a sample size comparable 
to the present study, Dwivedi et al.[12] 
reported an overall prevalence of TCP of 
8%, 4% of cases being severe, and attributed 
this to the high prevalence of anaemia in 
their patients.[12]
There are several reasons why the TCP 
in the women in the present study was 
probably gestational: (i) the prevalence rates 
are comparable to those reported in other 
series;[1,2] (ii) in most of the women with TCP 
who had two readings (22/26 HIV-infected 
women and 18/21 HIV-uninfected women), 
the platelet counts returned to normal in 
the postpartum period; and (iii) most of 
the women had mild TCP, in keeping with 
previous reports on gTCP.[1,2] Of the women 





Age (years)  26.7 26 0.048
Weight (kg)  80.7 79.8 0.774
Parity  1.0  1.0 0.667
Height (m)  1.7  1.8 0.272
Gestational age (wks)  36.8 37 0.051
Hb (g/dL)  11.1 11.7 <0.001
WCC (× 109/L)  7.8  8.7 <0.001
Lymphocytes (× 109/L)  2.1  2.2 0.907
Platelets (× 109/L) 243.2 247.4 0.354
Table 2. Thrombocytopenia at baseline
HIV-positive according to CD4 count  
(cells/µL) (N=669) HIV-negative
(N=642)Platelets (× 109/L) <200 200 - 350 351 - 500 >500
<100, n 0 0 3 1 3
100 - 150, n 6 10 8 12 27
%* 15.0 25.0 27.5 32.5
Total, n (%) 40 (6.0)† 30 (4.7)†
*% of HIV-positive and HIV-negative women with TCP.
†RR 1.28 (CI 0.81 - 2.03); p=0.292. 
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with TCP at 6 weeks, low platelet counts had been detected in the 
antenatal period in 3 in each HIV group, and their TCP was mild 
(>100 × 109/L), a feature not in keeping with ITP. One woman 
(patient 7 in Table 4) who had antenatal and post-delivery platelet 
counts of 81 × 109/L and 92 × 109/L, respectively, may in fact have 
had ITP, although it has been reported that it may take as long as 
12 weeks after delivery for platelet counts to recover,[13] and follow-
up in the present study did not extend beyond 6 weeks. ITP could 
also have been responsible for the new development of TCP in 
2 HIV-uninfected participants, as no other explanation could be 
found. Classic ITP occurs in the second or third decade of life,[3] 
and complicates 1/1 000 - 10 000 pregnancies.[12] In a report of 117 
patients with TCP at term, Subbiah et al.[14] found 41% of cases 
to be gestational and 26% to be due to ITP. However, this was a 
selected high-risk group and does not represent the general obstetric 
population.
The development of new-onset TCP in 3 HIV-infected women 
could have been related to their HIV status. In the first case (patient 
4 in Table 4), TCP was probably due to defec tive production of 
platelets. This woman was severely immunocompromised and had 
a low Hb and total WCC both at baseline and 6 weeks after delivery. 
She was not receiving any ART, in the context of Dominguez 
et al.’s[10] finding that untreated HIV-infected thrombocytopenic 
individuals had lower platelet turnover than those treated with 
zidovudine. The TCP in the other 2 women was probably immune-
mediated HIV-associated TCP, since both had relatively high CD4 
counts. Immunologically competent HIV-infected individuals 
(as opposed to those who are immunosuppressed) would be 
expected to produce more antiplatelet antibodies, leading to 
increased platelet destruction; among 41 HIV-infected individuals 
with TCP, platelet destruction was more prominent in patients 
with high CD4 counts.[10] It could be argued that the TCP in the 
HIV-infected participants (patients 1 - 3 in Table 4) that was 
detected both in the antenatal period and at 6 weeks was also 
immunologically induced. If that is so, the prevalence of HIV-
related TCP during pregnancy in the present study would be 0.9%, 
and while low platelet counts occurred mainly among women 
with CD counts of >200 cells/µL, the TCP was mild. While other 
studies have reported a relationship between the severity of the 
HIV infection and the occurrence or severity of TCP,[7] this was 
not confirmed in the present study. Ambler et al.[15] documented 
similar findings in a population of highly active antiretroviral 
therapy (HAART) recipients. 
As this was a retrospective analysis, maternal TCP could not 
be correlated with neonatal platelet counts. However, the findings 
are relevant to inform clinical practice, serving as a baseline. In 
the current era of universal HAART for all pregnant HIV-infected 
women, it can be expected that HIV-related TCP will be less frequent. 
While it is recommended that all efforts be made to acquire a baseline 
Hb and platelet count for all patients who are about to give birth, a 
fresh sample is not always indicated, as some clinicians have insisted 
for fear of HIV-related TCP. This causes delay in management and 
may potentially lead to poor perinatal outcomes.
Conclusion
This analysis establishes that TCP in HIV-infected pregnant women 
is mainly a result of the pregnancy itself, and that HIV-related TCP 
is rare, even in women not receiving ART. This is reassuring for 
practitioners managing women who present ‘unbooked’ in labour 
and perhaps require emergency caesarean section, but for whom 
a previous platelet count is unavailable. A baseline FBC, including 
Hb and platelets, should ideally be obtained as part of antenatal care 
during the course of pregnancy, but needs to be repeated during 
labour only in women with pre-eclampsia or obstetric haemorrhage.
Table 3. Baseline and 6-week platelet counts according to HIV status
Baseline platelets  
(× 109/L)
6-week platelets (× 109/L)
Total<150 >150 
HIV-infected, n (%)
<150 3 (11.5) 23 (88.5) 26
>150 3 (0.7) 432 (99.3) 435
HIV-uninfected, n (%)
<150 3 (15.0) 18 (85.7) 21
>150 2 (7.2) 413 (92.8) 415






Platelets at 6 weeks,
× 109/L
CD4 at 6 weeks,
cells/µL Probable cause
HIV-infected
 TCP at both 
assessments
1 101 235 114 253 ?gTCP, ?HIV-TCP
2 110 383 101 261 ?gTCP, ?HIV-TCP
3 133 116 113 170 ?gTCP, ?HIV-TCP
 TCP only at 6 
weeks
4 158 58 49 68 HIV-TCP
5 205 703 124 792 HIV-TCP
6 164 314 148 510 HIV-TCP
HIV-uninfected
 TCP at both 
assessments
7 81 92 ITP
8 126 109 ?gTCP
9 82 119 ?gTCP
 TCP only at 6 
weeks 
10 278 94 ?ITP
11 197 129 ?ITP
HIV-TCP = HIV-associated thrombocytopenia.
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